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Features		 RAI	Only	 RAI	+	Lithuim	 P-value	
Patients	(M/F)	 75	(11/64)	 88	(9/79)	 0.6545	
Mean	age	+/-	SD	 48.40	+/-	12.04	 43.68	+/-13.24	 1.0000	
Graves’	disease	 62	(83%)	 72	(82%)	 1.0000	
Toxic	nodular	disease	 13	(17%)	 16	(18%)	 1.0000	
Pretreatment	with	ATDs	 55	(57%)	 42	(43%)	 0.6605	
29	
	
Mean	T4	at	V1	(pmol/l)	 33.72	+/-	20.50	 34.83	+/-24.55	 0.637	






























































































































































































































































	 	 RAI	Only	 RAI	+Lithium	























































	 	 RAI	Only	 RAI	+Lithium	
Female	 V1	 34.98499	 35.0149	
V2	 24.739	 23.913	
V3	 18.439	 11.395	
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Appendix	D:	“Turnit	in”	report	
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